'Firecrest Through the Body' combines Firecrest’s clinical pharmacology and graphic design expertise to create a truly unique, animated view of systems inside the body.
ICON aims to address an unmet need for a well-defined, reliable endpoint that can measure the effects of antibacterial drugs on HABP patients.
Net new business awards of $468M, backlog grew to $3.5B, revenue up 14.1% YOY to $388M aand EPS was 79c.
Cynthia voted following a global industry survey conducted by vaccine industry organisation, VaccineNation. Cynthia was the only CRO representative included in the list.
Dr. Spector is an expert in clinical development and brings to ICON over 25 years of experience in managing global drug and medical device development programmes.
New members join Novartis, Janssen, and Eli Lilly to develop adaptive design and execution methodologies for improved decision-making in exploratory studies.
Quarter 2 net revenue increased 12.5% year on year to $376 million; income from operations was $48.3 million and EPS was 64 cents.
5-day education programme led by key opinion leaders from the pricing and market access industry and academia.
ICON experts will educate attendees on a range of topics, including innovative partnering models and outsourcing strategies, risk-based monitoring, functional service provision, novel adaptive design approaches and clinical outcomes assessment.